CURRICULO VITAE Lair Geraldo Theodoro Ribeiro, M.D., F.A.C.C. ?· indexadas, o Dr. Lair Ribeiro também…

Download CURRICULO VITAE Lair Geraldo Theodoro Ribeiro, M.D., F.A.C.C. ?· indexadas, o Dr. Lair Ribeiro também…

Post on 29-Nov-2018

213 views

Category:

Documents

0 download

Embed Size (px)

TRANSCRIPT

  • 1

    CURRICULO VITAE

    Lair Geraldo Theodoro Ribeiro, M.D., F.A.C.C.

    Formado em Medicina h mais de 45 anos, cardiologista, mestre em cardiologia pela PUC-RIO, nutrlogo pela ABRAN e Associao Mdica Brasileira, o Dr. Lair Ribeiro morou durante 17 anos nos Estados Unidos, perodo em que trabalhou em trs universidades americanas: Harvard Medical School, Baylor College of Medicine e Thomas Jefferson University. Nesse perodo, tambm exerceu os cargos de diretor-mdico na Merck Sharp & Dohme e diretor-executivo, alcanando a vice-presidncia, na Ciba Corporation, hoje Novartis.

    Autor de mais de 100 trabalhos cientficos publicados em revistas mdicas americanas indexadas, o Dr. Lair Ribeiro tambm publicou 38 livros, sendo 15 deles best sellers, 26 traduzidos para outros idiomas, hoje disponveis em mais de 40 pases.

    Por mais de 20 anos, proferiu palestras em diversas cidades brasileiras, vrios pases da Amrica do Sul, Amrica Central, Amrica do Norte e Europa. Treinou mais de 4.000 mdicos brasileiros na rea de Adequao Nutricional e Otimizao da Homeostase.

    Atualmente, o Dr. Lair Ribeiro professor de ps-graduao da Uning Centro Universitrio Ing, instituio avaliada pelo MEC, em 2017, como o quarto melhor centro universitrio do pas, o segundo da regio Sul e o melhor do Paran.

    Intitulado Adequao Nutricional e Manuteno da Homeostase Preveno e Tratamento de Doenas relacionadas Idade, o curso de ps-graduao lato sensu da Uning Centro Universitrio Ing, coordenado e ministrado pelo Dr. Lair Ribeiro, tem 18 meses de durao, 360 horas de sala de aula, 16 provas e uma monografia de concluso.

    1. TTULO ACADMICO

    1.1 Especialista em Cardiologia - Prova de ttulo pelo Conselho Federal de Medicina, em 03 de Outubro de 2013.

    2.1 Especialista em Nutrologia Prova de ttulo pelo Conselho Federal de Medicina,

    em 03 de Setembro de 2013.

    3.1 Curso de Medicina Quntica - Integral de acordo com seus Estatutos, com a Carga Horria de100 Horas. Instituto Brasileiro de Metodologia Quntica (IBMQ-lab) em 08 de Dezembro de 2001.

    4.1 Mestre em Cincias Mdicas - Cardiologia,pela Pontifcia Universidade Catlica

    do Rio de Janeiro - 1982.

  • 2

    5.1 Residncia em Cardiologia na Pontifcia Universidade Catlica do Rio de Janeiro/RJ, Brasil, em 1973.

    6.1 Research Fellow in Medicine - Peter Bent Brigham Hospital and Harvard Medical

    School, Boston (MA), USA, 1976 a 1978.

    7.1 Fellow in Cardiology - The Methodist Hospital Baylor College of Medicine, Houston (TX), USA, de 1978 a 1980.

    8.1 Graduao em Medicina pela Universidade Federal de Juiz de Fora UFJF,

    Estado de Minas Gerais, Brasil, em 1972.

    2. FORMAO EXTRACURRICULAR 1.2 NLP Master Certification, NLP Comprehensive Bouler, (CO), USA, 1990. 2.2 Management Development Program, Northeastern University, Boston, MA, USA,

    1987.

    3.2 NPL Practioner Certification, New York NLP Institute, New York (NY), USA, 1985 a 1986.

    3. ATIIVIDADES DOCENTES

    1.3 Professor e Coordenador do curso de Ps-Graduao lato sensu da Uning Centro Universitrio Ing, intitulado Adequao Nutricional e Manuteno da Homeostase Preveno e Tratamento de Doenas relacionadas Idade.

    2.3 Director Clinical Research Merck Sharp & Dohme Research Laboratories, West Point (PA), USA, 1982 a 1985.

    3.3 Adjunct Associate Professor Thomas Jefferson College of Medicine Philadelphia (PA), USA, 1984.

    4.3 Adjunct Assistant Professor Thomas Jefferson College os Medicine, Philadelphia (PA), USA, 1981 a 1984.

    5.3 Professor Assistente em Cardiologia na Escola de Medicina de Barbacena, Minas Gerais, Brasil, 1975 a 1976.

    6.3 Instrutor no curso de Ps-Graduao em Cardiologia, na Pontifcia Universidade Catlica do Rio de Janeiro, Brasil, 1974.

    7.3 Professor Assistente em Cardiologia na Universidade Federal de Juiz de Fora, Minas Gerais, Brasil, 1971 a 1972.

  • 3

    8.3 Teaching Assistant in Anatomy, Medical School of the Federal University of Juiz de

    Fora, Minas Gerais, Brazil, 1969 a 1971.

    4. ATIVIDADES PROFISSIONAIS

    4.1 PRESENT POSITION 4.1.1 President, International Support, Inc., desde fevereiro de 2016. 4.1.2 Confere o Mrito por relevantes servios prestados cidade e coletividade de

    Juiz de Fora. Mrito Comendador Henrique Guilherme Fernando Halfeld. 31 de Maio de 2006.

    4.1.3 Eleito membro ativo do American College of Cardiology, desde1983. 4.1.4 President, International Support, Inc.Scientific and Management Consultants

    Watchung (NJ), since fev. 1989. 4.1.5 Eleito membro ativo da The New York Academy of Sciences, desde 1980. 4.1.6 Pesquisador bolsista em Cardiolgia no Departamento de Medicina de Baylor

    College of Medicine, Houston, Texas, 1980. 4.1.7 Membro associado do The Peter Bent Brigham Hospital, Division of the Affiliated

    Hospitals Center, Inco, Boston, Massachusetts, 1978. 4.2. OTHER AFFILIATIONS

    1986 National Association of Neuro-Linguistic Programming

    1985 American Hear Association's Councils of Circulation and Basic Science

    1983 American College of Cardiology

    1983 Who's Who in Frontier Science Technology

    1981 New York Academy of Science

    1980 American Federation of Clinical Research

    1974 Brazilian Cardiology Society

    4.3. OUTRAS ATUAES

  • 4

    4.3.1 Acting Vice-Presidente Cardiovascular Drug Development, CIBA-GEIGY Corporation Pharmaceutical Division, Summit (NJ), USA, de 1988 a 1989.

    4.3.2 Chairman of Transderm-Nitro Defense CIBA-GEIGY Corporation Pharmaceutical

    Division, Summit (NJ), USA, 1988 a 1989. 4.3.3 Executive Director, Cardiovasc Clinical Research, CIBA-GEIGY Corporation

    Pharmaceutical Division, Summit (NJ), USA, 1985-1988. 4.3.4 Director, Clinical Research Merck Sharp & Dohme Research Laboratories, West

    Point (PA), USA. 1982-1985.

    4.4. EXPERINCIA PROFISSIONAL NO BRASIL 4.4.1 Banco do Brasil, Tefilo Otoni, MG, Brasil, 1964 a 1966. 4.4.2 Cardiologista, PRO-Cardaco Hospital, 1964 a 1966. 4.4.3 Cardiologista, Hospital So Lucas, Tefilo Otoni, MG, Brasil, 1974 a 1976. 5. PRODUO INTELECTUAL

    5.1 ARTIGOS PUBLICADOS

    1. Ribeiro LGT. Sal: Ingerir ou no ingerir? Vilo ou Heri? Brazilian Journal of Surgery and Clinical Research-BTSCR. Vol 13.n.1, pp. 06-11 (Dez 2015-Fev2016)

    2. Ribeiro LGT. Sal: Deficincia de vitamina B12 uma epidemia invisvel ao servio de sade. Brazilian Journal of Surgery and Clinical Research-BTSCR. Vol 13.n.1, pp. C10-C13 (Dez 2015-Fev2016)

    3. Olivo R. ; Ribeiro LGT. Os 6.000 anos de histria medicinal do aloe vera. BJSCR Brazilian Journal of Surgery and Clinical Research. Vol 15, n.1, pp 129-133 (Jul- Ago, 2016). Os 6.000 anos da histria medicinal do aloe vera

    4. Ira J Kohn, LAIR G.T. Ribeiro: Phosphodiesterase Inhibitors. it role in heart failure therapy. Arq Bras Cardiol 54(6):361-365, 1990.

    5. LAIR Ribeiro, IRA J. Kohn: Novas Perspectivas no Controle da Hipercolesterolemia com Uso de Inibidores da HMG CoA Redutase. Arq. Bras Cardiol vol 54/3: 177-178, 1990.

    6. Brow L, Nusbaum IM and Ribeiro LGT: Quality of life:How to asess it in clinical trials. Arq Bras Cardiol 50(6): 365-368, 1988.

    7. Islami Y, Ribeiro LGT: Lipid lowering effects on cardiovascular morbility and mortality. Clinical evidence and therapeutic guidelines. Arq Bras Cardiol 51 ( 1 ) 43- 48,1988.

    8. Smith EF, Egan JW, Goodman FR, Zimmerman MB, Webb RL and Ribeiro LGT. Effects of two nonsulfhydryl angiotensin-converting enzyme inhibitors, CGS 14831 and CGS 16617, on myocardial damage and left-ventricular hypertrophy following coronary artery occlusion in the rat. Pharmacology 37:254-263, 1988.

  • 5

    9. Ribeiro LGT, Price BA and Irvin JD: Antiarrhythmic effects of timolol in patients with ventricular arrhythmias. Arq Bras Cardiol 51(4) 359-364, 1988.

    10. Vik-Mo H, Hastie R. Chir B and Ribeiro LGT : Hemodynamic and metabolic evaluation of an acute left ventricular failure model induced y coronary artery embolization. Arq ras Carcdiol 48(3).13 g-145, 1987,

    11. Ribeiro LGT Hypertension. A paramount cardiovascular risk-factor in the western world. Arq Bras Cardiol 49(4):245-248, 1987.

    12. Sweet CS, Emmert SE, Stabilito ll and Ribeiro LGT: Increased survival in rats with congestive heart failure treated with enalapril. J Cardiovasc Pharmacol 10(6).639- 642, 1987.

    13. Lin SK and Ribeiro LGT: Kinetics of transdermal clonidine. Arch Intern Med 147:1681, 1987.

    14. Sweet CS, Ludden CT, Adkins E, Seymour AA, Emmert S and Ribeiro LGT: Enalapril in experimental hypertension and acute heart failure: comparison with calcium channel blockers. J Cardiovasc Pharmacol 8(Suppl. 1):S 15 - S 19, 1986.

    15. Vik-Mo, Hjos OD, Neelv JR, Maroko PR and Ribeiro LGT: Limitation of myocardial infarct size by metabolic interventions that reduce accumulation of fatty acid metabolites in ischemic myocardium. Am Heart J 111(6): 1048 - 1054. 1986.

    16. Lefer DJ, Hock CE, Ribeiro LGT and Lefer AM: Effects of lisinopril, a new angiotensin converting enzyme inhibitor in a cyro-injury model of chronic left ventricular failure. Meth and Find Exptl Clin Pharmacol 8(6) 357-362, 1986.

    17. Ribeiro LGT, Kasdin SL, Snyder DL, Fisher MB and Irvin JD. Beneficial effects of timolol in digitalized patients with atrial fibrillation and a rapid ventricular response. Arq Bras Cardiol 46(3):211-215,1986.

    18. Hock CE, Ribeiro LGT and Lefer AM: Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute rnyocardial infarction. Am Heart J 109 222-228, 1985.

    19. Vlasses PH, Ribeiro LGT, Rotmensch HH, Bondi JV, Loper AE, Hichens M, Duniay MC and Ferguson RK: Initial evaluation of transdermal Timolol, serum concentrations and beta-blockade. J Cardiovasc Pharmacol 7.245-250, 1985.

    20. Ribeiro LGT and Walker J F: Aplicaes teraputicas dos inibidores da enzima convesora de angiotensina. Rev Bras Med 42(7).242-246, 1985.

    21. Vik-Mo H, Yasay G, Ribeiro LGT and Maroko PR: Comparatlve effects of dobutamine and corwin, a beta-adrenergic partial agonist, in experimental left ventricular failure. J Cardiovasc Pharmacol 7 784-790, 1985.

    22. Sweet CS, Ludden CT, Freerick CM, Ribeiro LGT, Nussberger J. Slater EE and Blaine EH: Hemodynamic effects of synthetic atrial natriuretic factor (ANF) in dogs with acute left ventricular failure. European Jornal of Pharmacology, 115:267-276, 1985.

    23. Davis RF, DeBoar LW, Yasuda T, Rude RE, Ribeiro LGT and Maroko PR. Regional myocardial lidocaine concentration determines the antidysrythmic effect in dogs after coronary artery occlusion. Anesthesiology 62(2):155-60, 1985.

    24. Ribeiro LGT and Kasdin SL: Identification of high risk patients after an acute myocardial infarction Therapeutic approach for secondary prevention. Arq Bras Cardiol 44(3) 207-212, 1985.

  • 6

    25. Vik-Mo H, Maroko PR and Ribeiro LGT: Comparative effects of proranolol, timolol and metoprolol on myocardial infarct after size experimental coronary artery occlusion. J AmCollege of Cardiology 4(4): 735-741, 1984.

    26. Sweet CS, Ludden CT, Frederick CM and Ribeiro LGT: Hemodynamic effects of antiotensin and renin inhibition in dogs with acute left ventricular failure. Am J Med 77:7-12, 1984.

    27. Sweet CS, Ludden CT, Frederick CMK, Bush LR and Ribeiro LGT: Comparative hemodynamic effects of enalaprilat (MK-422), a converting enzyme inhibitor in dogs with acute left ventricular failure. J C Pharmacol 6:1067-1075, 1984.

    28. Ribeiro LGT and Kasdin SL: Prognosis after an acute myocardial infarction secondary prevention. Rev Lat Car 5(6).561-569,1984.

    29. Faria DB, Cheung W-m, Ribeiro LGT and Maroko PR: Effects of lidocaine and droxicainide on myocarial necrosis: A comparative study. J Am Coll Cardiol 1(6).1447-1452,1983.

    30. Endo T, Ribeiro LGT, Cheung W-m, Faria DB, Petranto MS and Maroko PR Relationship between the extent of the hypoperfused zone of the myocardium and the occurrence of ventricular fibrillation. Am Heart J 105(6): June, 1983.

    31. Ribeiro LGT and Davies RO: Reduction in Cardiac Death and Reinfarction Rates Caused by Beta-Blockers After Acute Myocardial Infarction. Rev Port Cardiol 2(5):389-392, 1983.

    32. Ribeiro LGT: Uso de bloqueadores beta-adrenonrgico aps infarto do miocrio. Arq. Bras Cardiol 40(2): 73-76, 1983.

    33. Ribeiro LGT and Lefer AM. Etiology an pathophysiology of coronary artery spasm chapter 2, Coronary Artery Spasm Robert A Char!ne. Editor, rlount Kisco, NY, Futura Puhlishing Company, 39-64, 1983.

    34. Maroko PR, Ribeiro LGT and Golderg S: Acute myocardial infarction Coronary thrombosis and salvage of the ischemic myocardiumts. Goldberg, S (ed) FA Davis, CO.Phila., PA, Cardiovascular Clinic Series, 14:(1 ) 191 -202, 1983.

    35. Sweet CS, Gaul SL, Reitz PM, Blaine EH and Ribeiro LGT: Mechanism of action of enalapril in experimental hypertension and acute left ventricular failure. J Hypertension 1 (Suppl 1):53-63, 1983.

    36. Ribeiro LGT, Brandon TA, Horak JK, Ware JA, Miller RR and Solis RT: Inhibition of platelet aggregation by verapamil: Quantification by in vivo and in vitro techniques. Cardiovasc Pharm 4 170-173, 1982.

    37. Ribeiro LGT, Cheung W-m and Maroko PR. Influence of the extent of the zone at risk on the effectiveness of drugs in reducing infarct size. Circulation 66: 181-186, 1982.

    38. Yasuda T, Ribeiro LGT and Maroko PR. Effect of hyaluronidase on experimental cerebral infarct size an mortality. Laboratory Investigation 46:400-404,1982.

    39. Ribeiro LGT, Zalewski A and Maroko PR: Limitation of infarct size: Mechanisms o interventions, methods of evaluation and clinical applications. In Treatment of Myocardial Ischemia, Ed Pedro Zarco, Editorial Alhampra S A, Madrid Spain, 1982.

    40. Hortak JK, Brandon TA, Ribeiro LGT, Ware JA Miller RR and Solis RT: Effects of Ethanol and Hemolysis on In Vivo and In Vitro Platelet Aggregation. J Cardiovasc Pharm 4 (6). 1037-1041, 1982.

  • 7

    41. Yasuda T, Holmarl BL, Ribeiro LGT, Alpert JS and Maroko PR. Accuracy of localization of acute myocardial infarction by 12 lead electrocardiography. JElectrocardiology 15(2):181-188, 1982.

    42. Ribeiro LGT, Spadaro J, Brandon TA, Kim H-S, Titus JL, Maroko PR and Miller RR. Efeitos do methoxy-verapamil (D600) na mortalidade e tamanho do infarto aps ocluso coronariana em ratos. Arq Bras Cardiol 37;85-88, 1981.

    43. Maroko PR, Chiariello M and Ribeiro LGT. The influence of vasodilators and vasoconstrictors on coronary collateral flow after experimental coronary artery occlusion. Les Alpha-Bloquants. Pharmacologie Experlmentale Et Clinique, Baumann, D, et al, Editors. Paris Symposium International, Masson PubIishing Company, 193-202, 1981.

    44. Iwasaki T, Ribeiro LGT, Faria DB Cheung W-m and Maroko PR: Importance of the source of hyaluronidase in determining protective effect on ischemic heart muscle in acute myocardial. Am Heart J 102 324-329, 1981.

    45. Miller RR, Ribeiro LGT, DeBauche TL and Brandon TA: Effects of prostacyclin and nitroprusside on mortality following experimental coronary artery occlusion, Chapter 13, Platelets and Prostaglandins in Cardiovascular Disease, Metha, J an Metha, P, Editors Mount Kisco, NY, Futura Publishing Company, 251-264. 1981.

    46. Quinones MA, Waggoner AD,...